Scott A. Armstrong, MD/PhD, collaborates with fellow Crazy 8 researchers in barcoding pediatric leukemia for therapeutic purposes. Dr. Armstrong is President of Dana-Farber Boston Children’s Cancer and Blood Disorders Center, Chairman of the Department of Pediatric Oncology at Dana-Farber Cancer Institute, David G. Nathan Professor of Pediatrics at Harvard Medical School, and the Associate Chief of the Division of Hematology/Oncology at Boston Children’s Hospital.

His career aims to delineate the biology of childhood cancers and the development of new therapeutic approaches for children with cancer. He continues to focus on the development of new therapeutics that target chromatin-based mechanisms and the development and translation of several new small molecule approaches that are being tested in children and adults with cancer.

Dr. Armstrong’s work has been recognized with awards such as the Paul Marks Prize for Cancer Research from Memorial Sloan Kettering Cancer Center, the E. Mead Johnson Award from the Society for Pediatric Research, and the Dameshek Prize from the American Society of Hematology. In addition, he is a member of the National Academy of Medicine.

Dr. Armstrong is the recipient of an ALSF-funded Innovation Grant in 2017 for his work targeting BRD9 in sarcoma and worked on other ALSF-funded projects like targeting fusion driven sarcomas with a Crazy 8 Pilot Grant in 2019.